Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 10

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 10
---
 of the next steps and development path for the program, and therefore the potential range of R&D capital needed” Confident in Management’s Ability to Execute as Evidenced By HEPLISAV - B Excited About Upside Potential of Growing HEPLISAV - B Franchise Supportive of Management’s Disciplined Capital Allocation Strategy Source: Select Wall Street Research 11 |

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx … And Are Excited About Dynavax’s Promising Internal Clinical Pipeline and Value Creation Opportunities © Copyright DYNAVAX 2025 Nov 21, 2024 TD Cowen “The [Phase 2 Shingles] results demonstrate proof of concept, suggesting the vaccine is safe, potentially effective, with the possibility for reduced post - injection reactions compared to market - leader Shingrix… Dynavax has a viable candidate that could offer a better tolerability profile and capture a meaningful portion of this multibillion - dollar market ” Feb 21, 2025 William Blair ” The company’s strong balance sheet and cash - flow - positive HEPLISAV - B business will continue to support the exploration of novel CpG 1018 based vaccines in the company’s pipeline and potential external business development opportunities . This has allowed the company to explore the use of CpG 1018 in additional vaccines as it seeks to build out a vaccine pipeline” Feb 21, 2025 TD C owen ” Dynavax has established a number of collaborations around the novel adjuvant in HEPLISAV, CpG 1018, to explore its utility in enhancing the efficacy of other vaccines … Dynavax’s commercial COVID - 19 vaccine supply agreements generated $588MM in CpG 1018 revenue during 2022. These agreements highlight the potential long - term value that CpG could bring if it is incorporated into successful vaccines” Opportunity for Differentiated Shingles Vaccine in Multi - Billion - Dollar Market Pipeline Powered by Innovative CpG 1018 Adjuvant Clinically Proven Adjuvant Enables Potential for Long - Term Value Creation Source: Select Wall Street Research 12 |

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX